| EXPLANATION OF AMENDMENTS |
THE SUSAN G KOMEN BREAST CANCER FOUNDATION, INC. FORM 990 IS BEING AMENDED TO REFLECT THE CORRECT INVESTMENT VALUE FOR STOCK THAT WAS DONATED TO THE FOUNDATION. THE FINAL VALUATION OF THE STOCK WAS NOT COMPLETED WHEN THE ORIGINAL RETURN WAS FILED. VOLUNTEERS FORM 990, PART I, QUESTION 6 VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE SUSAN G. KOMEN 3 DAY SERIES. FORM 990, PART III - PROGRAM SERVICE ACCOMPLISHMENTS SUSAN G. KOMEN IS A LEADING GLOBAL BREAST CANCER ORGANIZATION, FUNDING MORE BREAST CANCER RESEARCH THAN ANY OTHER NONPROFIT WHILE PROVIDING REAL TIME HELP TO THOSE FACING THE DISEASE. SINCE ITS FOUNDING IN 1982, KOMEN HAS FUNDED MORE THAN $920 MILLION IN BREAST CANCER RESEARCH AND PROVIDED $2 BILLION IN FUNDING FOR PATIENT NAVIGATION, SCREENING, DIAGNOSIS, TREATMENT, EDUCATION, HEALTH SYSTEMS IMPROVEMENT, AND PSYCHOSOCIAL SUPPORT PROGRAMS SERVING MILLIONS OF PEOPLE IN MORE THAN 30 COUNTRIES WORLDWIDE. KOMEN WAS FOUNDED BY NANCY G. BRINKER, WHO PROMISED HER SISTER, SUSAN G. KOMEN, THAT SHE WOULD END THE DISEASE THAT CLAIMED SUZY'S LIFE. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. KOMEN'S RESEARCH PROGRAMS ARE DESIGNED TO UNDERSTAND THE BIOLOGY OF BREAST CANCER AND ADVANCE THE TRANSLATION OF RESEARCH DISCOVERIES INTO NEW WAYS TO DETECT, DIAGNOSE, TREAT AND PREVENT BREAST CANCER, In order TO REDUCE BREAST CANCER INCIDENCE AND MORTALITY WITHIN THE NEXT DECADE. IN FISCAL YEAR 2016, KOMEN AWARDED OVER 100 GRANTS THROUGH ITS RESEARCH PROGRAMS TO SUPPORT SCIENTIFIC RESEARCH, COLLABORATIONS AND TRAINING IN THE UNITED STATES AND OTHER COUNTRIES, INCLUDING AUSTRALIA, BELGIUM, CANADA, GERMANY, PUERTO RICO, AND THE UNITED KINGDOM. WE CONSIDER IT OUR RESPONSIBILITY TO ENSURE THE CONTINUITY OF BREAST CANCER RESEARCH FOR THE FUTURE. WITH FEDERAL RESEARCH BUDGETS TIGHTENING, WE CANNOT AFFORD TO LOSE PROMISING YOUNG INVESTIGATORS FOR LACK OF FUNDING. TO THAT END, KOMEN AWARDED POSTDOCTORAL FELLOWSHIPS, GRADUATE TRAINING IN DISPARITIES RESEARCH AND CAREER CATALYST RESEARCH GRANTS TO SUPPORT YOUNG INVESTIGATORS IN THE FIELD OF BREAST CANCER RESEARCH. KOMEN'S RESEARCH INVESTMENT THROUGH THE ABOVE GRANT MECHANISMS SUPPORTS PROJECTS THAT AIM TO, AMONG OTHER THINGS: A) DEVELOP TARGETED THERAPIES FOR TRIPLE-NEGATIVE BREAST CANCER, B) UNDERSTAND BREAST CANCER PROGRESSION AND METASTASIS, C) PREDICT RISK USING IMAGING, D) REDUCE TOXICITY IN BREAST CANCER RADIOTHERAPY, E) IMPROVE TREATMENT RESPONSE, F) DEVELOP NEW IMAGING TECHNIQUES TO IMPROVE DIAGNOSIS, AND G) UNDERSTAND THE LINK BETWEEN OBESITY AND BREAST CANCER. EACH MECHANISM IS FURTHER DESCRIBED BELOW: POSTDOCTORAL FELLOWSHIPS (PDF): PDF GRANTS SEEK TO ATTRACT AND SUPPORT PROMISING SCIENTISTS EMBARKING ON CAREERS DEDICATED TO BREAST CANCER RESEARCH WHO HAVE NO MORE THAN 3 YEARS POST-COMPLETION OF THEIR MOST RECENT CLINICAL FELLOWSHIP, 5 YEARS POST-COMPLETION OF THEIR MOST RECENT RESIDENCY (FOR PHYSICIANS) OR 5 YEARS POST-COMPLETION OF THEIR MOST RECENT PHD. BY PROVIDING FUNDING TO OUTSTANDING POSTDOCTORAL/POSTGRADUATE FELLOWS UNDER THE GUIDANCE OF A MENTOR, KOMEN SEEKS TO ENSURE THAT A DIVERSE POOL OF HIGHLY TRAINED SCIENTISTS WILL EMERGE AS THE NEXT GENERATION OF LEADERS IN THE FIELD OF BREAST CANCER RESEARCH. PDF GRANTS PROVIDE SUPPORT FOR RESEARCH PROJECTS THAT HAVE SIGNIFICANT POTENTIAL TO ADVANCE OUR UNDERSTANDING OF BREAST CANCER, LEAD TO REDUCTIONS IN BREAST CANCER INCIDENCE AND/OR MORTALITY AND MOVE US TOWARD OUR GOAL OF A WORLD WITHOUT BREAST CANCER. GRADUATE TRAINING IN DISPARITIES RESEARCH (GTDR): GTDR GRANTS ARE INTENDED TO ESTABLISH AND/OR TO SUSTAIN A TRAINING PROGRAM DEDICATED TO UNDERSTANDING AND ELIMINATING DISPARITIES IN BREAST CANCER OUTCOMES ACROSS POPULATION GROUPS. AT LEAST THREE GRADUATE STUDENTS, PREFERABLY THOSE FROM POPULATIONS AFFECTED BY DISPARITIES IN BREAST CANCER OUTCOMES, ARE SUPPORTED. CAREER CATALYST RESEARCH (CCR): CCR GRANTS PROVIDE UNIQUE OPPORTUNITIES FOR SCIENTISTS WHO HAVE HELD FACULTY POSITIONS FOR NO MORE THAN 6 YEARS AT THE TIME OF FULL APPLICATION TO ACHIEVE RESEARCH INDEPENDENCE. CCR GRANTS PROVIDE SUPPORT FOR HYPOTHESIS-DRIVEN RESEARCH PROJECTS THAT HAVE SIGNIFICANT POTENTIAL TO ADVANCE OUR UNDERSTANDING OF BREAST CANCER, LEAD TO REDUCTIONS IN BREAST CANCER INCIDENCE AND/OR MORTALITY AND MOVE US TOWARD OUR GOAL OF A WORLD WITHOUT BREAST CANCER. KOMEN ALSO OFFERS RESEARCH GRANTS THAT SUPPORT SPECIAL RESEARCH PROJECTS, PROGRAMS AND COLLABORATIONS THAT LEVERAGE RESEARCH AND COMMUNITY RESOURCES TO FACILITATE THE DEVELOPMENT OF THE INFRASTRUCTURE, TOOLS, AND OTHER MEANS TO ACCELERATE THE TRANSLATION OF SCIENTIFIC DISCOVERIES FROM BENCH TO BEDSIDE TO CURBSIDE. FUNDING FROM ORGANIZATIONS LIKE KOMEN AND ITS SUPPORTERS HAS PROVEN CRITICAL FOR ALL THESE ACTIVITIES, ESPECIALLY AT A TIME OF DIMINISHING FEDERAL FUNDING FOR CANCER RESEARCH AND FOR CLINICAL TRIALS. EXAMPLES OF THESE GRANTS COMMITTED IN FISCAL YEAR 2016 INCLUDE: METASTATIC BREAST CANCER PROJECT: SUPPORT FOR THE METASTATIC BREAST CANCER (MBC) PROJECT WHICH SEEKS TO EMPOWER PATIENTS TO ACCELERATE MBC RESEARCH BY SHARING THEIR SAMPLES AND CLINICAL INFORMATION. THE GOAL IS THAT THIS APPROACH WILL LEAD TO MORE RAPID DISCOVERIES IN METASTATIC BREAST CANCER AND HELP IDENTIFY NEW THERAPEUTIC STRATEGIES. THE PROJECT WORKS BY ASKING PATIENTS WITH METASTATIC BREAST CANCER ACROSS THE COUNTRY TO PARTICIPATE BY SHARING A PORTION OF THEIR STORED TUMOR SAMPLES, A SALIVA SAMPLE, AND COPIES OF THEIR MEDICAL RECORDS. THIS APPROACH ALLOWS PATIENTS WHO DO NOT CURRENTLY HAVE THE OPPORTUNITY TO PARTICIPATE IN RESEARCH THROUGH CLINICAL TRIALS - the vast majority of cancer patients in the U.S. - to say "count me inparticipate in metastatic breast cancer research directly. Within this project, Komen supports the "young patients with metastatic breast cancer" study because breast cancer is the leading cause of cancer-related deaths in women age 40 and younger. YOUNG WOMEN ARE MORE LIKELY TO DEVELOP MORE AGGRESSIVE SUBTYPES OF BREAST CANCER AND SURVIVAL RATES FOR YOUNG WOMEN WITH BREAST CANCER ARE LOWER THAN FOR OLDER WOMEN. THE GOAL OF THIS STUDY IS TO CHARACTERIZE THE TUMOR AND GERMLINE FROM 50-100 YOUNG PATIENTS WITH METASTATIC BREAST CANCER TO BETTER UNDERSTAND THE BIOLOGICAL MECHANISMS FOR THESE AGE DISPARITIES IN BREAST CANCER OUTCOMES. FRIENDS OF CANCER RESEARCH CONFERENCE ON CLINICAL RESEARCH: SUPPORT FOR THE FRIENDS OF CANCER RESEARCH (FOCR) TO CONVENE A CONFERENCE ON CLINICAL CANCER RESEARCH. THIS CONFERENCE ADDRESSES CRITICAL ISSUES IN NEW DRUG DEVELOPMENT AND APPROVAL. THIS EVENT BRINGS TOGETHER APPROXIMATELY 250 LEADERS FROM FEDERAL HEALTH AND REGULATORY AGENCIES, ACADEMIC RESEARCH CENTERS, PATIENT ADVOCACY ORGANIZATIONS AND THE PRIVATE SECTOR TO IDENTIFY CHALLENGES, PROPOSE CONSENSUS SOLUTIONS AND DEVELOP A CLEAR PATH FORWARD ON CRITICAL ISSUES SURROUNDING THE DEVELOPMENT AND REGULATION OF DRUGS AND THERAPIES. THE 2015 CONFERENCE HIGHLIGHTED THE FOLLOWING THREE TOPICS: INTEGRATING ALTERNATIVE MEASURES OF TUMOR RESPONSE INTO DRUG DEVELOPMENT, BLURRING OF PHASE 1, 2 AND 3 TRIALS IN ONCOLOGY (EXPANSION COHORTS IN EARLY DRUG DEVELOPMENT), AND MEASURING PATIENT-REPORTED OUTCOMES IN PRE-MARKET STUDIES. -GLOBAL BIOLOGICAL STANDARDS INSTITUTE TRANING MODULE: SUPPORT TO THE GLOBAL BIOLOGICAL STANDARDS INSTITUTE (GBSI) TO DEVELOP A TRAINING MODULE TO IMPROVE CELL AUTHENTICATION PRACTICE AMONG BREAST CANCER RESEARCHERS. CELL LINES ARE CRITICAL TOOLS IN PRECLINICAL BASIC CANCER RESEARCH BECAUSE THEY ARE THE FOUNDATION FOR FURTHER INVESTIGATION WHICH MAY LEAD TO NEW DIAGNOSTICS AND TREATMENTS. IT IS THEREFORE IMPORTANT FOR RESEARCHERS TO MAKE SURE THAT THE CELLS THEY ARE USING IN THEIR RESEARCH ARE AUTHENTICATED, I.E., THE CELLS ARE WHAT THEY THINK THEY ARE AND ARE FREE OF CONTAMINATION FROM OTHER CELLS OR MICROBES. APPROXIMATELY 15-36% OF RESEARCH INVOLVING CELL LINES USES CELLS THAT ARE CONTAMINATED OR MISIDENTIFIED. THE GBSI WILL DEVELOP A FREELY AVAILABLE, online "active learning" module in cell authentication that equips CANCER RESEARCHERS WITH EXPERT INSTRUCTIONAL VIDEOS, COUPLED WITH A DISSEMINATION CAMPAIGN THAT WILL DECREASE RESEARCH REPRODUCIBILITY PROBLEMS INVOLVING CELL LINES AND IMPROVE RESEARCH PRACTICE. THIS PROJECT WILL ENSURE MORE EFFECTIVE USE OF HUNDREDS OF MILLIONS OF DOLLARS IN RESEARCH EXPENDITURES WHILE SPEEDING THE DEVELOPMENT OF NEW THERAPIES THAT CAN REDUCE THE INCIDENCE AND MORTALITY OF BREAST CANCER. EDUCATION, PATIENT SUPPORT AND PATIENT NAVIGATION KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CON |
| Significant changes to governing documents |
FORM 990, PART VI, QUESTION 4 SIGNIFICANT CHANGES DURING FISCAL YEAR 2016: - ESTABLISHED THE MAXIMUM NUMBER OF DIRECTORSHIPS AT 15 - ESTABLISHED A MAXIMUM TOTAL FOR CLASS IV DIRECTORS AT 11 |
| DESCRIBE THE PROCESS USED BY MANAGEMENT &/OR GOVERNING BODY TO |
REVIEW 990 FORM 990, PART VI, QUESTION 11B MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVELS OF MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS REVIEWS AND MAKES AN APPROVAL RECOMMENDATION REGARDING THE FORM 990 TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS APPROVES THE FORM 990 PRIOR TO THE FORM BEING FILED. |
| DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICTS OF |
INTEREST FORM 990, PART VI, QUESTION 12C KOMEN PRODUCES AN ANNUAL SURVEY REQUIRING ALL EMPLOYEES, BOARD MEMBERS, COMMITTEE MEMBERS, AND ADVISORY BOARDS TO DISCLOSE ANY POTENTIAL OR ACTUAL CONFLICTS OF INTEREST THEY MAY HAVE. ANY CONFLICTS ARE THEN REVIEWED BY MANAGEMENT AND THE AUDIT COMMITTEE AND APPROPRIATE MEASURES ARE TAKEN. ALL EMPLOYEES, BOARD MEMBERS, COMMITTEE MEMBERS AND ADVISORY BOARDS ARE REQUIRED TO UPDATE THEIR CONFLICT OF INTEREST DISCLOSURES AS NECESSARY DURING THE YEAR. |
| OFFICES & POSITIONS FOR WHICH PROCESS WAS USED, & YEAR PROCESS |
WAS BEGUN FORM 990, PART VI, QUESTIONS 15A AND 15B THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE PRESIDENT/CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER EMPLOYEES; GRANTING THE CEO AUTHORITY TO DETERMINE ACTUAL COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. FOR THE POSITION OF PRESIDENT/CEO, EXTERNAL BENCHMARKING WAS CONDUCTED TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION. |
| AVAIL OF GOV DOCS, CONFLICT OF INTEREST POLICY, & FIN STMTS TO |
GEN PUBLIC FORM 990, PART VI, QUESTION 19 KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE, AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 AND THE CONFLICT OF INTEREST POLICY ARE NOT ONLINE BUT ARE AVAILABLE TO THE PUBLIC UPON REQUEST. |
| ADDITNL DETAIL ON EVENT PRODUCTION EXPENSES INCLUDED on other exp |
FORM 990, PART IX, LINE 24 Komen pays 80% of the cost of all T-shirts for the Susan G. Komen Race for the Cure events conducted by the Komen Affiliates during the year. |
| OTHER CHANGES IN NET ASSETS OR FUND BALANCES |
FORM 990, PART XI, LINE 9 Rescinded Grants $8,384,244 Rounding $1 ---------- Total $8,384,245 ========== |
Attach to Form 990 or 990-EZ.